BR112014014418A2 - proteínas de fusão fc de receptor igf solúvel e usos das mesmas - Google Patents

proteínas de fusão fc de receptor igf solúvel e usos das mesmas

Info

Publication number
BR112014014418A2
BR112014014418A2 BR112014014418A BR112014014418A BR112014014418A2 BR 112014014418 A2 BR112014014418 A2 BR 112014014418A2 BR 112014014418 A BR112014014418 A BR 112014014418A BR 112014014418 A BR112014014418 A BR 112014014418A BR 112014014418 A2 BR112014014418 A2 BR 112014014418A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
igf
igf receptor
soluble igf
receptor
Prior art date
Application number
BR112014014418A
Other languages
English (en)
Portuguese (pt)
Inventor
Massie Bernard
Brodt Pnina
Sulea Traian
Original Assignee
Nat Res Council Canada
The Royal Inst For The Advancement Of Learning/Mcgill Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Council Canada, The Royal Inst For The Advancement Of Learning/Mcgill Univ filed Critical Nat Res Council Canada
Publication of BR112014014418A2 publication Critical patent/BR112014014418A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
BR112014014418A 2011-12-15 2012-12-14 proteínas de fusão fc de receptor igf solúvel e usos das mesmas BR112014014418A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576034P 2011-12-15 2011-12-15
PCT/CA2012/050899 WO2013086636A1 (en) 2011-12-15 2012-12-14 Soluble igf receptor fc fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
BR112014014418A2 true BR112014014418A2 (pt) 2019-09-24

Family

ID=48611766

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014418A BR112014014418A2 (pt) 2011-12-15 2012-12-14 proteínas de fusão fc de receptor igf solúvel e usos das mesmas

Country Status (9)

Country Link
US (1) US10538575B2 (https=)
EP (1) EP2791338B1 (https=)
JP (1) JP2015505843A (https=)
KR (1) KR20150031217A (https=)
CN (1) CN104066845A (https=)
BR (1) BR112014014418A2 (https=)
CA (1) CA2858389A1 (https=)
HK (1) HK1202587A1 (https=)
WO (1) WO2013086636A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR102654033B1 (ko) * 2014-12-08 2024-04-02 1글로브 바이오메디칼 씨오., 엘티디. 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도
WO2016193497A1 (en) * 2015-06-04 2016-12-08 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
CN107921094B (zh) * 2015-06-04 2022-03-01 圣拉斐尔医院有限公司 Igfbp3及其用途
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN106520806B (zh) * 2016-11-03 2018-06-19 宜明细胞生物科技有限公司 一种重组car基因及其载体、car-t细胞和应用
EP3632929A1 (en) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
CN113092392B (zh) * 2021-03-05 2022-11-08 苏州西山中科药物研究开发有限公司 一种检测猴血清中靶向可溶性蛋白的单克隆抗体药物总浓度的通用型方法
CN119708266B (zh) * 2025-02-26 2025-06-06 首玺(广州)医疗科技有限责任公司 一种胰岛素样生长因子-1连接多肽及其在子宫内膜损伤修复中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6084085A (en) 1995-11-14 2000-07-04 Thomas Jefferson University Inducing resistance to tumor growth with soluble IGF-1 receptor
ES2305886T3 (es) * 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007021807A1 (en) * 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
JP2010518140A (ja) * 2007-02-14 2010-05-27 グラクソ グループ リミテッド Ｉｇｆ−１ｒに対する新規抗体
AU2008223541B2 (en) * 2007-03-02 2012-04-05 Amgen Inc. Methods and compositions for treating tumor diseases
CA2694055A1 (en) * 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
JP2011526792A (ja) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
JP2011529452A (ja) * 2008-07-29 2011-12-08 ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ 抗血管新生薬としての可溶性ｉｇｆ受容体
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
WO2010136480A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins

Also Published As

Publication number Publication date
EP2791338A1 (en) 2014-10-22
EP2791338A4 (en) 2015-12-02
HK1202587A1 (en) 2015-10-02
US10538575B2 (en) 2020-01-21
JP2015505843A (ja) 2015-02-26
US20150044209A1 (en) 2015-02-12
KR20150031217A (ko) 2015-03-23
CA2858389A1 (en) 2013-06-20
WO2013086636A1 (en) 2013-06-20
EP2791338B1 (en) 2019-02-20
CN104066845A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
BR112014014418A2 (pt) proteínas de fusão fc de receptor igf solúvel e usos das mesmas
SA520420658B1 (ar) جزيئات ربط ضد bcma واستخداماتها
AR070453A1 (es) Anticuerpos dirigidos a angiopoyetina -1 y angiopoyetina-2 y usos de los mismos
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BR112013031892A2 (pt) anticorpos anti-psgl-1 e seu uso
MY192474A (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
TN2014000438A1 (en) Anti-fcrn antibodies
EA201400625A1 (ru) Антитела против pd-l1 и их применение
UY33588A (es) Moleculas de union a vegf
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
BR112015027313A2 (pt) anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
BR112015010740A2 (pt) Agentes para tratamento de doenças cancerosas expressando claudina
EA201400579A1 (ru) Антитела к il-36r
CO6460768A2 (es) Anticuerpos específicos para dkk-1 y sus usos
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
HK1250918A1 (zh) 用於胶质母细胞瘤的egfr导向的car疗法
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
EA201391509A1 (ru) Твердофазные формы кабазитаксела и способы их получения

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.